38924384|t|Brexpiprazole: A new option in treating agitation in Alzheimer's dementia-Insights from transgenic mouse models.
38924384|a|AIM: Brexpiprazole is the first FDA-approved treatment for agitation associated with dementia due to Alzheimer's disease. Agitation in Alzheimer's dementia (AAD) occurs in high prevalence and is a great burden for patients and caregivers. Efficacy, safety, and tolerability of brexpiprazole were demonstrated in the AAD clinical trials. To demonstrate the agitation-ameliorating effect of brexpiprazole in animals, we evaluated brexpiprazole in two AAD mouse models. METHODS: The resident-intruder test was conducted in 5- to 6-month-old Tg2576 mice, given vehicle or brexpiprazole (0.01 or 0.03 mg/kg) orally 1 h before the test. Locomotor activity was measured in 6-month-old APPSL-Tg mice given vehicle or brexpiprazole (0.01 or 0.03 mg/kg) orally the evening before the start of locomotor measurement for 3 days. RESULTS: In the resident-intruder test, Tg2576 mice showed significantly higher attack number and shorter latency to first attack compared to non-Tg mice. In the Tg mice, brexpiprazole treatment (0.03 mg/kg) significantly delayed the latency to first attack and showed a trend toward a decrease in attack number. APPSL-Tg mice ( 6 months old) showed significantly higher locomotion during dark period Phase II (Zeitgeber time [ZT] 16-20) and Phase III (ZT20-24) compared to non-Tg mice, correlating with the clinical observations of late afternoon agitation in Alzheimer's disease. Brexpiprazole treatment (0.01 and 0.03 mg/kg) significantly decreased hyperlocomotion during the Phase III in APPSL-Tg mice. CONCLUSION: The suppression of attack behavior and the reduction of nocturnal hyperlocomotion in these Tg mice may be indicative of the therapeutic effect of brexpiprazole on AAD, as demonstrated in the clinical trials.
38924384	0	13	Brexpiprazole	Chemical	MESH:C000591922
38924384	40	49	agitation	Disease	MESH:D011595
38924384	53	73	Alzheimer's dementia	Disease	MESH:D000544
38924384	99	104	mouse	Species	10090
38924384	118	131	Brexpiprazole	Chemical	MESH:C000591922
38924384	172	181	agitation	Disease	MESH:D011595
38924384	198	206	dementia	Disease	MESH:D003704
38924384	214	233	Alzheimer's disease	Disease	MESH:D000544
38924384	235	244	Agitation	Disease	MESH:D011595
38924384	248	268	Alzheimer's dementia	Disease	MESH:D000544
38924384	270	273	AAD	Disease	MESH:D000544
38924384	327	335	patients	Species	9606
38924384	390	403	brexpiprazole	Chemical	MESH:C000591922
38924384	429	432	AAD	Disease	MESH:D000544
38924384	469	478	agitation	Disease	MESH:D011595
38924384	502	515	brexpiprazole	Chemical	MESH:C000591922
38924384	541	554	brexpiprazole	Chemical	MESH:C000591922
38924384	562	565	AAD	Disease	MESH:D000544
38924384	566	571	mouse	Species	10090
38924384	651	657	Tg2576	CellLine	CVCL:S723
38924384	658	662	mice	Species	10090
38924384	681	694	brexpiprazole	Chemical	MESH:C000591922
38924384	800	804	mice	Species	10090
38924384	822	835	brexpiprazole	Chemical	MESH:C000591922
38924384	970	976	Tg2576	CellLine	CVCL:S723
38924384	977	981	mice	Species	10090
38924384	1079	1083	mice	Species	10090
38924384	1095	1099	mice	Species	10090
38924384	1101	1114	brexpiprazole	Chemical	MESH:C000591922
38924384	1252	1256	mice	Species	10090
38924384	1411	1415	mice	Species	10090
38924384	1478	1487	agitation	Disease	MESH:D011595
38924384	1491	1510	Alzheimer's disease	Disease	MESH:D000544
38924384	1512	1525	Brexpiprazole	Chemical	MESH:C000591922
38924384	1582	1597	hyperlocomotion	Disease	
38924384	1631	1635	mice	Species	10090
38924384	1715	1730	hyperlocomotion	Disease	
38924384	1743	1747	mice	Species	10090
38924384	1795	1808	brexpiprazole	Chemical	MESH:C000591922
38924384	1812	1815	AAD	Disease	MESH:D000544
38924384	Negative_Correlation	MESH:C000591922	MESH:D003704
38924384	Negative_Correlation	MESH:C000591922	MESH:D000544
38924384	Negative_Correlation	MESH:C000591922	MESH:D011595

